Zentalis reports 15.8-month median overall survival with azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer

By Public Technologies
  • Zentalis Pharmaceuticals announced its first overall survival results for azenosertib from DENALI Part 1b, published in an ESMO Congress 2026 abstract.
  • Survival was longer in Cyclin E1-positive platinum-resistant ovarian cancer patients than in the biomarker-negative subgroup, with no new safety signals observed.
  • The abstract reported favorable survival compared with historical single-agent chemotherapy benchmarks in the biomarker-positive group, not a direct trial comparison.
  • Results support further development in biomarker-selected patients through ongoing DENALI Part 2 and ASPENOVA Phase 3 confirmatory trials.
  • The data will be presented at ESMO Congress in Madrid on October 23, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610181805PRIMZONEFULLFEED9847969) on October 18, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.